Search

Displaying results 8141 - 8150 of 10000 in total
  1. Drug

    Ordopidine

    go.drugbank.com/drugs/DB05196
    Investigational

    ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses.

  2. Drug

    CYC116

    go.drugbank.com/drugs/DB05198
    Investigational

    CYC116 is a novel anticancer compound with a unique target profile involving both cell cycle and angiogenesis inhibition mechanisms. … Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which demonstrated anticancer activity with a mechanism consistent with inhibition

  3. Drug

    XL418

    go.drugbank.com/drugs/DB05204
    Investigational

    XL418 is a novel anticancer compound.

  4. Drug

    PS386113

    go.drugbank.com/drugs/DB05211
    Experimental

    PS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders. It is being developed by Schering-Plough and Pharmacopeia.

  5. Drug

    KD7040

    go.drugbank.com/drugs/DB05214
    Investigational

    KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07.

  6. Drug

    AM103

    go.drugbank.com/drugs/DB05225
    Experimental

    AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation

  7. Drug

    RDEA806

    go.drugbank.com/drugs/DB05228
    Investigational

    RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.

  8. Drug

    Hepatitis B immune globulin

    go.drugbank.com/drugs/DB05276
    ApprovedInvestigational

    Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines.

    Products: HEPATITIS B IMMUNOGLOBULIN P BEHRING, HEPATITIS B IMMUNOGLOBULIN P BEHRING 1000 IU/5 ML IM KULLANIMA HAZIR ENJEKTÖRDE ENJEKSİYONLUK ÇÖZELTİ
  9. Drug

    SPP 301

    go.drugbank.com/drugs/DB05290
    Investigational

    SPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy.

  10. Drug

    IDM-2

    go.drugbank.com/drugs/DB05293
    Experimental

    IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.